IL33 and asthma: According to reports, GSDMB may control the release of TSLP, IL-33, and IL-25, which are critical for the pathophysiology of asthma, by encouraging the infiltration of neutrophils and eosinophils in the inflamed airways; this is more pronounced in individuals with the T/C or T/T genotype [30].